Welcome to our dedicated page for Nuvasive news (Ticker: NUVA), a resource for investors and traders seeking the latest updates and insights on Nuvasive stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuvasive's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuvasive's position in the market.
NuVasive, Inc. (NASDAQ: NUVA) has launched the NuVasive Tube System (NTS) and Excavation Micro, expanding its minimally invasive surgery solutions for thoracolumbar procedures. This innovation aims to enhance workflow speed, safety, and reproducibility in spine surgeries. The NTS allows surgeons to perform multiple procedures with one system, emphasizing NuVasive's market leadership in access technology. The company will showcase its P360 portfolio at the upcoming NuVasive Innovation Event on November 16, with discussions led by company leadership and surgeon partners.
NuVasive, Inc. (NASDAQ: NUVA) will release its third quarter financial results on November 9, 2022, after the market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss the results for the quarter ending September 30, 2022. The company reported over $1 billion in net sales and operates in more than 50 countries. Investors can access the call via dial-in numbers or through a live webcast, which will also be archived on their website.
NuVasive, Inc. (NASDAQ: NUVA) has announced its ongoing partnership as a gold sponsor for EUROSPINE 2022, to be held in Milan from October 19-21. The company emphasizes its commitment to advancing spine care through innovative solutions. CEO Chris Barry highlighted the importance of collaboration with leading societies to enhance patient outcomes. NuVasive will conduct a workshop showcasing its Pulse® technology, demonstrating its integration in surgical settings. The company offers various expert-led sessions on its procedural innovations at their stand, enhancing knowledge and engagement within the spine surgery community.
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology innovation, has announced its Investor Day 2022 to be held on October 6, 2022, in San Diego. This hybrid event will feature presentations from key executives, including updates on the company’s strategy, innovation pipeline, and long-term financial goals through 2027. In-person attendees can participate in demonstrations of the C360 and X360 portfolios and the Pulse platform. Advance registration is required, and a replay will be available online after the event.
On September 28, 2022, NuVasive announced the launch of Reline Cervical, a new fixation system for posterior cervical fusion (PCF), enhancing its C360 portfolio. This innovation aims to address the $2.6 billion cervical spine market, enabling surgeons to perform complex surgeries using a comprehensive fixation system. The system integrates with NuVasive's Pulse technology for advanced navigation and intraoperative monitoring. The launch strengthens NuVasive's position as a leader in complex deformity solutions, furthering their goal to capture a larger market share.
NuVasive, Inc. (NASDAQ: NUVA) continues its commitment to the Society for Minimally Invasive Spine Surgery (SMISS) by sponsoring and attending the SMISS Annual Forum '22 in Las Vegas from September 29 to October 1, 2022. CEO Chris Barry emphasized the importance of research and education in advancing less invasive surgery, highlighting the company's X360 portfolio and Pulse technology. Attendees can engage with leadership and witness live demonstrations at booth #201/203. The event will also feature the Pioneer in Lateral Access Award during the SOLAS session on September 29.
NuVasive, Inc. (NASDAQ: NUVA) announced its continued partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor. This collaboration will be showcased at the 57th Annual Meeting held from September 14-17, 2022, in Stockholm, Sweden. CEO Chris Barry emphasized the importance of integrated technology in enhancing spine surgery. NuVasive will host a workshop discussing the MAGEC® system's long-term outcomes. The company has supported SRS since 2007, contributing to the education of over 1,500 professionals in spinal deformity treatment.
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology innovation, announced its participation in two upcoming investor conferences. On September 7, 2022, at the Wells Fargo Healthcare Conference in Boston, CFO Matt Harbaugh will present at 3:10 p.m. ET. Following that, on September 12, 2022, CEO Chris Barry and CFO Matt Harbaugh will speak at the Morgan Stanley 20th Annual Global Healthcare Conference in New York at 11:40 a.m. ET. Webcasts of the presentations will be available on their website for 30 days post-event.
NuVasive, Inc. (NASDAQ: NUVA) announced the resignation of Massimo Calafiore as executive vice president and chief commercial officer, effective August 31, 2022. Calafiore will join a privately-held orthopedics technology company as CEO. His responsibilities will be redistributed among current management as NuVasive aligns its commercial strategy. CEO Chris Barry praised Calafiore's contributions during his five-year tenure, highlighting the company's commitment to transforming spine surgery and improving patient care.
NuVasive reported second-quarter 2022 net sales of $310.5 million, reflecting a 5.3% increase year-over-year. The growth is attributed to new product launches and increased procedure volumes. GAAP diluted loss per share was ($0.02), with non-GAAP diluted earnings per share at $0.47. The company reiterated its full-year guidance for net sales growth of 6%-8% and updated GAAP diluted EPS guidance to $0.95-$1.25. Cash and cash equivalents stood at $226 million as of June 30, 2022.